Skip to content
Learn More

Resources

iBio’s Collaboration with South Africa’s AzarGen Biotechnologies Advances to Next Stage

September 18, 2019

NEW YORK, Sept. 17, 2019 (GLOBE NEWSWIRE) — iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”) today announced that it has entered into the initial Statement of Work (“SOW1”) under its Memorandum of Understanding (“MOU”) with AzarGen Biotechnologies (Pty.) Ltd. (“AzarGen”). Following iBio’s successful use of its technologies and manufacturing capabilities to advance the development …

Read More

iBio and CC-Pharming Expand Business Collaboration in China

August 27, 2019

iBio, Inc. (NYSE AMERICAN:IBIO) today announced that it has expanded the scope of its business venture with CC-Pharming Ltd. by granting it an exclusive, royalty-bearing commercial license to iBio’s bio-better rituximab (“iBio Rituximab”) product candidates for the territory of China. In addition, the Company will grant to CC-Pharming a research license to iBio’s FastPharming™ System and know-how …

Read More

iBio Inks 3D Bioprinting Agreement

August 19, 2019

iBio, Inc. (NYSE AMERICAN:IBIO) today announced that it has entered into a Master Services Agreement (“MSA”) with Lung Biotechnology PBC, a subsidiary of United Therapeutics Corporation (NASDAQ:UTHR), to produce recombinant human collagen (“rhCollagen”)-based bioink for 3D bioprinted organ transplants. iBio will collaborate with Lung Biotechnology PBC to scale-up production of rhCollagen in tobacco plants using …

Read More

iBio Announces First Agreement for Fill-Finish Services

June 19, 2019

NEW YORK, June 19, 2019 (GLOBE NEWSWIRE) — iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”) today announced the activation of its new cGMP sterile fill-finish services operation via the signing of a supply agreement with a clinical-stage biopharmaceutical company developing breakthrough gene and cell therapies (the “Customer”). Earlier in June, iBio introduced its new …

Read More

iBio Launches New Sterile Fill-Finish Services

June 3, 2019

NEW YORK, June 03, 2019 (GLOBE NEWSWIRE) — iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”) today introduced new cGMP sterile fill-finish capabilities for pharmaceutical products, including monoclonal antibodies, viral vectors, and other biologics. Designed for clients with preclinical and clinical stage programs, the operation is housed in the Company’s 135,000 square foot CDMO facility …

Read More
Top